Resources
National Strategic Framework for Chronic Conditions
The National Strategic Framework for Chronic Conditions 2026–2035 sets Australia’s long term plan to prevent and manage chronic illness. It guides governments, health services and communities to work together, focusing on prevention, integrated care, equity and shared risk factors.
Chronic Conditions Prevention and Integrated Care Program – Overview
Learn about the new Chronic Conditions Prevention and Integrated Care Program. It funds evidence‑based prevention, early detection and integrated care through national grants to improve outcomes and reduce health inequities.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 13 March 2026
Life Saving Drugs Program (LSDP) Expert Panel (the panel) agenda for the 23rd meeting on 13 March 2026.
Life Saving Drugs Program (LSDP) – Olipudase alfa (Xenpozyme®) outcome statement
Summary of the consideration of the application from Sanofi Australia and New Zealand for the inclusion of olipudase alfa (Xenpozyme®) on the LSDP for the treatment of acid sphingomyelinase deficiency (ASMD) types A/B and B.
Newborn bloodspot screening (NBS) – Delivering consistency and expansion fact sheet
This fact sheet provides information about what NBS expansion means for families and consumers, expansion progress to date, and upcoming milestones.
Newborn bloodspot screening (NBS) – Our national decision-making pathway fact sheet
This fact sheet provides information on the national NBS decision-making pathway, including the role of each committee in the process.
02:20
Newborn Bloodspot Screening Open Call
Newborn bloodspot screening programs improve the health of babies by identifying those at risk of developing serious conditions. An open call inviting the public to identify conditions for consideration for screening was open from 14 October 2025 and closed on 14 January 2026.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 31 October 2025
Life Saving Drugs Program (LSDP) Expert Panel (the panel) agenda for the 22nd meeting on 31 October 2025.
MyMedicare and Chronic Condition Management MBS items and Patient Case Studies
Changes to the MBS Chronic Condition Management Framework from 1 July 2025, aim to support high quality, continuous, multidisciplinary team-based care for patients.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 25 July 2025
Life Saving Drugs Program (LSDP) Expert Panel (the panel) agenda for the 21st meeting on 25 July 2025.
Chronic Wounds Consumable Scheme Product List
The Chronic Wounds Consumable Scheme will help eligible patients manage their chronic wounds by covering the full cost of products a patient needs to heal, such as bandages, dressings and adhesives.
Australian Thalidomide Survivors Support Program – EAF and HCAF guidelines
These guidelines contain the requirements to access support from the Extraordinary Assistance Fund (EAF) and Health Care Assistance Fund (HCAF) under the Australian Thalidomide Survivors Support Program.
The Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK) – PDF version
Type 2 diabetes is a common chronic disease. Many Australians are at risk of developing type 2 diabetes, especially if they have certain risk factors. This tool uses a brief list of questions to assess the risk of a person developing type 2 diabetes in the next 5 years.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 6 March 2025
Life Saving Drugs Program (LSDP) Expert Panel (the panel) agenda for the 20th meeting on 6 March 2025.
Avalglucosidase alfa Terms of Reference and Protocol Questions
This report outlines the Avalglucosidase alfa 24 Month Review Terms of Reference and Protocol Questions
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 13 December 2024
Life Saving Drugs Program (LSDP) Expert Panel (the panel) agenda for the 17th meeting on 13 December 2024.
Australian Government response to the Inquiry into childhood rheumatic diseases – Interim Report
This is the government response to the interim report on Inquiry into childhood rheumatic diseases.
Newborn bloodspot screening variant fact sheet
The list of variants for sickle cell disease, beta thalassemia and other hemoglobinopathies are captured in this resource.
Life Saving Drugs Program – Pompe disease – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Pompe disease for the first time, or after a break.
Life Saving Drugs Program – Gaucher disease (type 1) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.
Life Saving Drugs Program – Hereditary tyrosinaemia (type 1) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for hereditary tyrosinaemia (type 1) for the first time, or after a break.
Life Saving Drugs Program – Hereditary tyrosinaemia (type 1) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.
Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.
Life Saving Drugs Program – Late infantile Batten disease (CLN2 disease) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Batten disease for the first time, or after a break.
Life Saving Drugs Program – Mucopolysaccharidosis type VI (MPS VI) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.
Date last updated: